Transcutaneous immunization with bacterial ADP-ribosylating exotoxins as antigens and adjuvants

Infection and Immunity

Volumn 67, Issue 3, 1999, Pages 1100-1106

  Glenn, Gregory M ^a,b   Scharton Kersten, Tanya ^a,b   Vassell, Russell ^a,b   Matyas, Gary R ^a   Alving, Carl R ^a  

^a WALTER REED ARMY INSTITUTE OF RESEARCH   (United States)

^b IOMAI Corporation   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLERA TOXIN; DIPHTHERIA TOXOID; EXOTOXIN; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; IMMUNOLOGICAL ADJUVANT; PROTEIN SUBUNIT; TETANUS ANTIBODY; TETANUS TOXIN; TETANUS TOXOID;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; ARTICLE; CHOLERA; CONTROLLED STUDY; DOSE RESPONSE; DRUG DELIVERY SYSTEM; DRUG POTENCY; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOGLOBULIN BLOOD LEVEL; INTRANASAL DRUG ADMINISTRATION; MOUSE; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; TETANUS; TRANSDERMAL DRUG ADMINISTRATION;

EID: 0033009744     PISSN: 00199567     EISSN: None     Source Type: Journal    
DOI: 10.1128/iai.67.3.1100-1106.1999     Document Type: Article

References (36)

1. Aylward, B., J. Lloyd, M. Zaffran, R. McNair-Scott, and P. Evans. 1995. Reducing the risk of unsafe injections in immunization programmes: financial and operational implications of various injection technologies. Bull. W.H.O. 73:531-540.
2. Brink, P. R. G., A. M. van Loon, J. C. M. Trommelen, F. W. J. Gribnau, and I. R. O. Smale-Novakova. 1985. Virus transmission by subcutaneous jet injection. J. Med. Microbiol. 20:393-397.
3. Centers for Disease Control. 1986. Hepatitis B associated with jet gun injection - California. Morbid. Mortal. Weekly Rep. 35:373-376.
4. Clements, J. D., R. J. Yancey, and R. A. Finkelstein. 1980. Properties of homogeneous heat-labile enterotoxin from Escherichia coli. Infect. Immun. 29:91-97.
5. Clements, J. D., M. Jertborn, D. Sack, B. Stanton, J. Holmgren, M. R. Khan, and S. Huda. 1986. Effect of neutralization of gastric acid on immune responses to an oral B subunit, killed whole cell cholera vaccine. J. Infect. Dis. 154:175-178.
6. Clements, J. D., D. A. Sack, J. R. Harris, J. Chakraborty, P. K. Neogy, B. Stanton, N. Huda, M. U. Khan, A. K. Bradford, M. Ansaruzzaman, M. Yunus, M. R. Rao, A.-M. Svennerholm, and J. Holmgren. 1988. Cross-protection by B subunit-whole cell cholera vaccine against diarrhea associated with heat-labile toxin-producing enterotoxigenic Escherichia coli: results of a large-scale field trial. J. Infect. Dis. 158:372-377.
7. Clements, M. L. 1912. Influenza vaccines, p. 129-150. In R. W. Ellis (ed.), Vaccines: new approaches to immunological problems. Butterworth-Heinemann, Boston, Mass.
8. Cuatrecasas, P. 1973. Interaction of Vibrio cholerae enterotoxin with cell membranes. Biochemistry 12:3547-3558.
9. De, S. N. 1959. Enterotoxicity of bacteria-free culture-filtrate of Vibrio cholerae. Nature 183:1533-1534.
10. Dickinson, B. L., and J. D. Clements. 1995. Dissociation of Escherichia coli heat-labile enterotoxin adjuvanticity from ADP-ribosyltransferase activity. Infect. Immun. 63:1617-1623.
11. Elson, C. O., and W. Ealding. 1984. Cholera toxin feeding did not induce oral tolerance in mice and abrogated oral tolerance to an unrelated protein antigen. J. Immunol. 133:2892-2897.
12. Fairweather, N. F., V. A. Lyness, and D. J. Maskell. 1987. Immunization of mice against tetanus with fragments of tetanus toxin synthesized in Escherichia coli. Infect. Immun. 55:2541-2545.
13. Giuliani, M. M., G. Del Giudice, V. Giannelli, G. Dougan, G. Douce, R. Rappuoli, and M. Pizza. 1998. Mucosal adjuvanticity and immunogenicity of LTR72, a novel mutant of Escherichia coli heat-labile enterotoxin with partial knockout of ADP-ribosyltransferase activity. J. Exp. Med. 187:1123-1132.
14. Glenn, G. M., M. Rao, G. R. Matyas, and C. R. Alving. 1998. Skin immunization made possible by cholera toxin. Nature 391:851.
15. Glenn, G. M., T. Scharton-Kersten, R. Vassell, C. P. Mallet, T. L. Hale, and C. R. Alving. 1998. Transcutaneous immunization with cholera toxin protects mice against lethal mucosal toxin challenge. J. Immunol. 161:3211-3214.
16. Goldblatt, D., A. R. Vaz, and E. Miller. 1998. Antibody avidity as a surrogate maker of successful priming by Haemophilus influenzae type b conjugate vaccines following infant immunization. J. Infect. Dis. 177:1112-1115.
17. Holmgren, J., A.-M. Svennerholm, O. Ouchterlony, A. Andersson, G. Walletstrom, and U. Westerberg-Berndtsson. 1975. Antitoxic immunity in experimental cholera: protection and serum and local antibody responses in rabbits after enteric and parenteral immunization. Infect. Immun. 12:1331-1340.
18. Holmgren, J., and A.-M. Svennerholm. 1977. Mechanisms of disease and immunity in cholera: a review. J. Infect. Dis. 136:S105-S112.
19. Holmgren, J., A.-M. Svennerholm, M. Jertborn, J. Clements, D. A. Sack, R. Salenstedt, and H. Wigzell. 1992. An oral B subunit: whole cell vaccine against cholera. Vaccine 10:911-914.
20. Kauppi, M., J. Eskola, and H. Kayhty. 1995. Anticapsular polysaccharide antibody concentrations in saliva after immunization with Haemophilus influenzae type b conjugate vaccines. Pediatr. Infect. Dis. J. 14:286-294.
21. 2-macroglobulin receptor/low density lipoprotein receptor-related protein binds and internalizes Pseudomonas exotoxin A. J. Biol. Chem. 267:12420-12423.
22. Krueger, K. M., and J. T. Barbieri. 1995. The family of bacterial ADP-ribosylating exotoxins. Clin. Microbiol. Rev. 8:34-47.
23. Levine, M. M., J. B. Kaper, R. E. Black, and M. L. Clements. 1983. New knowledge on pathogenesis of bacterial enteric infections as applied to vaccine development. Microbiol. Rev. 47:510-550.
24. Lobet, Y., C. W. Cluff, and W. Cieplak. 1991. Effect of site-directed mutagenic alterations on ADP-ribosyltransferase activity of the A subunit of Escherichia coli heat-labile enterotoxin. Infect. Immun. 59:2870-2879.
25. Lycke, N. 1997. The mechanism of cholera toxin adjuvanticity. Res. Immunol. 148:504-520.
26. McComb, J. A. 1964. The prophylactic dose of homologous tetanus antitoxin. N. Engl. J. Med. 270:175-178.
27. Miller, K. D., R. D. Gibbs, M. M. Mulligan, T. B. Nutman, and D. P. Francis. 1983. Intradermal hepatitis B virus vaccine: immunogenicity and side effects in adults. Lancet ii:1454-1456.
28. Murphy, B. R., D. L. Nelson, P. F. Wright, E. L. Tierney, M. A. Phelan, and R. M. Chanock. 1982. Secretory and systemic immunological response in children infected with live attenuated influenza A virus vaccines. Infect. Immun. 36:1102-1108.
29. National Research Council. 1996. Guide for the care and use of laboratory animals. National Research Council, Washington, D.C.
30. Pierce, N. F., E. A. Kaniecki, and R. S. Northrup. 1972. Protection against experimental cholera by antitoxin. J. Infect. Dis. 126:606-616.
31. Schneerson, R., J. B. Robbins, J. Taranger, T. Lagergard, and B. Trollfors. 1996. A toxoid vaccine for pertussis as well as diphtheria? Lessons to be relearned. Lancet 348:1289-1292.
32. Snider, D. P. 1995. The mucosal adjuvant activities of ADP-ribosylating bacterial enterotoxins. Crit. Rev. Immunol. 15:317-348.
33. Tamura, S., H. Funato, T. Nagamine, C. Aizawa, and T. Kurata. 1989. Effectiveness of cholera toxin B subunit as an adjuvant for nasal influenza vaccination despite pre-existing immunity to CTB. Vaccine 7:503-505.
34. Udey, M. C. 1997. Cadherins and Langerhans cell immunobiology. Clin. Exp. Immunol. 107(Suppl. 1):6-8.
35. Whittle, H. C., W. H. Lamb, and R. W. Ryder. 1987. Trials of intradermal hepatitis vaccines in Gambian children. Ann. Trop. Paediatr. 7:6-9.
36. Zachoval, R., F. Deinhardt, L. Gurtler, J. Eisenburg, and G. Korger. 1988. Risk for virus transmission by jet injection. Lancet ii:189. (Letter.)